Kuros Biosciences AG
- Jurisdiction
Switzerland - LEI
5299006U5POB2AVTT709 - ISIN
CH0325814116 (KURN.SW )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. Read full profile
Fundamentals
- Net revenue
€116.79M - Gross margin
86.4% - EBIT
-€9.54M - EBIT margin
-8.2% - Net income
-€19.28M - Net margin
-16.5%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| N/A | N/A |
|
|
|
|
| N/A | N/A |
|
|
|
|
| N/A | N/A |
|
|
|
|